Kalaris Therapeutics, Inc. (KLRS) › Shareholders' EquityKalaris Therapeutics, Inc. (KLRS) — Shareholders' EquityAnnual figures by fiscal year, from SEC filings.2018: -$30.62M2019: -$51.50M2020: $353.06M2021: $225.27M2022: $224.52M2023: -$45.02M2024: -$96.62M2025: $78.81M$78.81M2018Shareholders' Equity (USD)2025Fiscal YearShareholders' EquityChange YoY2025$78.81M+181.6%2024-$96.62M-114.6%2023-$45.02M-120.1%2022$224.52M-0.3%2021$225.27M-36.2%2020$353.06M+785.5%2019-$51.50M-68.2%2018-$30.62M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share